• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    SC 13G/A 1 p24-3222sc13ga.htm WARBY PARKER INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*
     

    Warby Parker Inc.

    (Name of Issuer)
     

    Class A Common Stock, $0.0001 par value

    (Title of Class of Securities)
     

    93403J106

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 93403J10613G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    D1 Capital Partners L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,861,364

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,861,364

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,861,364

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.8%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 93403J10613G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Daniel Sundheim

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    27,200

    6

    SHARED VOTING POWER

    7,861,364

    7

    SOLE DISPOSITIVE POWER

    27,200

    8

    SHARED DISPOSITIVE POWER

    7,861,364

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,888,564

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.8%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

     

    CUSIP No. 93403J10613G/APage 4 of 7 Pages

     

    Item 1(a). Name of Issuer.
       
      Warby Parker Inc. (the "Issuer")

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
       
     

    233 Spring Street, 6th Floor East

    New York, New York 10013

     

    Item 2(a). Name of Person Filing.
       
      This statement is filed by D1 Capital Partners L.P. (the "Investment Manager") and Daniel Sundheim (the "Mr. Sundheim").  The foregoing persons are hereinafter sometimes referred to as the "Reporting Persons."
       
      The Investment Manager is a registered investment adviser and serves as the investment manager of private investment vehicles and accounts, including D1 Capital Partners Master LP (the "Investment Vehicle"), and may be deemed to beneficially own the shares of Class A Common Stock held by the Investment Vehicle and/or its subsidiary. Mr. Sundheim indirectly controls the Investment Manager and may be deemed to beneficially own the shares of Class A Common Stock held by the Investment Vehicle and/or its subsidiary.
       
      The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the securities reported herein.

     

    Item 2(b). Address of Principal Business Office.
       
     

    D1 Capital Partners L.P.

    9 West 57th Street, 36th Floor

    New York, New York 10019

       
     

    Daniel Sundheim

    c/o D1 Capital Partners L.P.

    9 West 57th Street, 36th Floor

    New York, New York 10019

     

    Item 2(c). Place of Organization.
       
     

    Investment Manager – Delaware

    Mr. Sundheim – United States of America

     

    Item 2(d). Title of Class of Securities.
       
      Class A common stock, $0.0001 par value (the "Class A Common Stock")

     

    Item 2(e). CUSIP Number.
       
      93403J106

     

    CUSIP No. 93403J10613G/APage 5 of 7 Pages

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) x

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ______________________________________________________

     

    Item 4. Ownership.
       
      The information required by Items 4(a) – (c)  is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  
       
      The percentages set forth herein are calculated based upon 100,657,415 shares of Class A Common Stock outstanding as of August 6, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 8, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.

     

    CUSIP No. 93403J10613G/APage 6 of 7 Pages

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      The Investment Vehicle (and/or its subsidiary) has the right to receive and the power to direct the receipt of dividends from, and the proceeds from the sale of, the shares of Class A Common Stock reported herein.  

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
      Not applicable.

     

    Item 10. Certification.
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 93403J10613G/APage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024  
      D1 Capital Partners L.P.
       
      By: /s/ Amanda Hector
      Name: Amanda Hector
      Title: General Counsel and Chief Compliance Officer
       
       
       
       
      /s/ Daniel Sundheim
      DANIEL SUNDHEIM
             

     

     

    Get the next $WRBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    2/5/2025$19.00 → $23.00Neutral → Sell
    Citigroup
    1/17/2025$23.00Outperform → In-line
    Evercore ISI
    11/19/2024$22.00 → $26.00Outperform
    Telsey Advisory Group
    11/8/2024$19.00 → $22.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Warby Parker upgraded by Citigroup with a new price target

      Citigroup upgraded Warby Parker from Sell to Neutral and set a new price target of $17.00

      4/30/25 1:18:55 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker upgraded by Loop Capital with a new price target

      Loop Capital upgraded Warby Parker from Hold to Buy and set a new price target of $27.00

      4/17/25 8:27:42 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

      Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $30.00 from $28.00 previously

      2/28/25 8:48:26 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cutler Joel E disposed of 5,656,571 shares (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/18/25 9:52:05 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Chief Financial Officer Miller Steven Clive sold $274,808 worth of shares (11,684 units at $23.52), was granted 15,128 shares, covered exercise/tax liability with 6,321 shares and converted options into 27,731 shares, increasing direct ownership by 14% to 204,727 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/6/25 6:02:10 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Co-Chief Executive Officer Gilboa David Abraham converted options into 3,271 shares, sold $4,772,513 worth of shares (202,968 units at $23.51), was granted 23,250 shares, covered exercise/tax liability with 12,858 shares and converted options into 201,088 shares, increasing direct ownership by 96% to 24,089 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/5/25 9:57:41 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      8/14/24 4:52:02 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

      Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

      8/1/24 4:15:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Target and Warby Parker Team Up to Bring Stylish, Affordable Eyewear to More Consumers

      New Warby Parker at Target shop-in-shops will offer guests designer-quality eyewear as well as contacts and eye exams Five shop-in-shops will debut in 2025 with plans to open more in the years aheadMINNEAPOLIS and NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Target Corporation (NYSE:TGT) and Warby Parker (NYSE:WRBY) are partnering to bring designer-quality, affordable eyewear to even more consumers through the retailer's newest shop-in-shop, Warby Parker at Target. Each Warby Parker at Target shop-in-shop will offer products and services — including glasses, sunglasses, contacts, e

      2/27/25 7:15:00 AM ET
      $TGT
      $WRBY
      Department/Specialty Retail Stores
      Consumer Discretionary
      Ophthalmic Goods
      Health Care

    $WRBY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Warby Parker Inc.

      10-Q - Warby Parker Inc. (0001504776) (Filer)

      5/8/25 5:10:13 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Warby Parker Inc. (0001504776) (Filer)

      5/8/25 6:46:05 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • SEC Form DEFA14A filed by Warby Parker Inc.

      DEFA14A - Warby Parker Inc. (0001504776) (Filer)

      5/6/25 5:07:56 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Financials

    Live finance-specific insights

    See more
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Announces Fourth Quarter and Full Year 2024 Results

      Q4 net revenue increased 17.8% year over year; 2024 net revenue increased 15.2% year over year Active Customers increased 7.8% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2024. "Our strong 2024 results highlight the power of Warby Parker's brand and unmatched value proposition combined with our team's high-quality execution. We delivered on our ambitious goals to accelerate revenue growth, customer growth and glasses growth, all while maintaining operational discipline and expanding p

      2/27/25 6:45:00 AM ET
      $TGT
      $WRBY
      Department/Specialty Retail Stores
      Consumer Discretionary
      Ophthalmic Goods
      Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 5:08:23 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 1:30:16 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/12/24 10:40:28 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care